Wyeth invests L3.25M in UK site

USA-based drug major Wyeth has announced a wave of new investments at its New Lane site in Havant in the UK. The firm explained that the move is in response to growing demand for its pneumococcal meningitis vaccine Prevnar. The new investment, which totals around L3.25 million ($6.5 million), has allowed the installation of a second packaging line for the product that will see the facility produce a projected 22 million units this year. In addition, a second vaccine, Meningitec, will be packaged at the site. Wyeth has also sold its facility in Blois in France to distribution company Depolabo, marking another phase of the firm's withdrawal from the country that was initiated in 2005 with a 1.80 billion euro ($2.45 billion) investment in new production facilities in Ireland.